Skip to main content
. 2022 Aug 16;140(15):1674–1685. doi: 10.1182/blood.2022016293

Figure 5.

Figure 5

OS from randomization for patients with FLT3mutat AML diagnosis by MRD status at baseline (after chemotherapy) and randomized treatment arm. MRD was determined at study entry by multiparameter flow cytometry using a different-from-normal method with a 0.1% positivity threshold. FLT3mut includes both FLT3-ITD and FLT3-TKD mutations.